APO-CANDESARTAN TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
29-01-2019
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
CANDESARTAN CILEXETIL
Tilgængelig fra:
APOTEX INC
ATC-kode:
C09CA06
INN (International Name):
CANDESARTAN
Dosering:
8MG
Lægemiddelform:
TABLET
Sammensætning:
CANDESARTAN CILEXETIL 8MG
Indgivelsesvej:
ORAL
Enheder i pakken:
100/500
Recept type:
Prescription
Terapeutisk område:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Produkt oversigt:
Active ingredient group (AIG) number: 0135220002; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2011-04-26
Produktets egenskaber
_APO-CANDESARTAN Tablets Product Monograph_
Page 1 of 34
PRODUCT MONOGRAPH
PR
APO-CANDESARTAN
CANDESARTAN CILEXETIL TABLETS USP
4 MG, 8 MG, 16 MG AND 32 MG
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
JANUARY 29, 2019
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 222632
_APO-CANDESARTAN Tablets Product Monograph_
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 3
_SUMMARY PRODUCT INFORMATION
.................................................................................................
3_
_INDICATIONS AND CLINICAL USE
.......................................................................................................
3_
_CONTRAINDICATIONS
...........................................................................................................................
3_
_WARNINGS AND
PRECAUTIONS..........................................................................................................
4_
_ADVERSE REACTIONS
..........................................................................................................................
7_
_DRUG INTERACTIONS
.........................................................................................................................
13_
_DOSAGE AND ADMINISTRATION
.......................................................................................................
16_
_OVERDOSAGE
.....................................................................................................................................
18_
_ACTION AND CLINICAL PHARMACOLOGY
........................................................................................
18_
_STORAGE AND STABILITY
..................................................................................................................
21_
_DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................................
21_
PART II: SCIENTIFIC INFORMATION
..................
Læs hele dokumentet
